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Abstract
Angiogenesis is crucial for lung development. Although there has been considerable exploration, the mechanism by which
lung vascular and alveolar formation is controlled is still not completely understood. Here we show that low-density
lipoprotein receptor-related protein 5 (LRP5), a component of the Wnt ligand-receptor complex, regulates angiogenesis and
alveolar formation in the lung by modulating expression of the angiopoietin (Ang) receptor, Tie2, in vascular endothelial
cells (ECs). Vascular development in whole mouse lungs and in cultured ECs is controlled by LRP5 signaling, which is, in turn,
governed by a balance between the activities of the antagonistic Tie2 ligands, Ang1 and Ang2. Under physiological
conditions when Ang1 is dominant, LRP5 knockdown decreases Tie2 expression and thereby, inhibits vascular and alveolar
development in the lung. Conversely, when Ang2 dominates under hyperoxia treatment in neonatal mice, high LRP5 and
Tie2 expression suppress angiogenesis and lung development. These findings suggest that the LRP5-Tie2-Ang signaling axis
plays a central role in control of both angiogenesis and alveolarization during postnatal lung development, and that
deregulation of this signaling mechanism might lead to developmental abnormalities of the lung, such as are observed in
bronchopulmonary dysplasia (BPD).
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Introduction
The formation of the pulmonary capillary vessels and dynamic
postnatal alveolar formation are tightly coupled processes; new
alveolar septa are formed with the closely associated capillaries
that protrude into primitive air space to increase the surface area,
which is available for gas exchange [1–3]. Angiogenesis, the
formation of capillary network, plays a critical role in this process
and a potent angiogenic growth factor, vascular endothelial
growth factor (VEGF) plays an important role in postnatal lung
alveolar development [4] as well as the maintenance of alveolar
structures in adult lung [5,6]. The inhibition of VEGF not only
impairs pulmonary vascular network development, but also leads
to the formation of immature alveoli [7–9]. Thus, angiogenesis is
known to play crucial roles in physiological lung development [10–
15], and deregulation of this process leads to lung pathologies such
as bronchopulmonary dysplasia (BPD) [7,9]. In addition to VEGF,
the angiopoietin (Ang)-Tie2 pathway also contributes to angio-
genesis [16–18] by modulating migration and intercellular
remodeling of endothelial cells (ECs) [19–22]. Importantly, Tie2
and Angs are extensively expressed in lung and deregulation of this
system contributes to the pathogenesis of various lung diseases
including pulmonary fibrosis and asthma [23,24]. Ang1 and Ang2
bind to their common receptor Tie2, antagonize each other and
control blood vessel maturation and stabilization during angio-
genesis [25,26]; Ang1 stabilizes blood vessel formation [21,27],
whereas Ang2 destabilizes the blood vessel structure in lung injury
such as BPD [11,28,29]. Given that the level of Ang1 dynamically
increases, while Ang2 decreases in the lung after birth [30] and
that tracheal aspirate samples from the BPD model mouse have
high levels of Ang2 [31,32], the Ang/Tie2 pathway may play
a crucial role in postnatal lung vascular and alveolar development.
However, the precise mechanisms by which the Ang/Tie2
pathway regulates lung organ morphogenesis during normal
development and in pathology have not been elucidated.
Wntsignalingisalsoakeyregulatorinlungvasculardevelopment
[33–38] and deregulation of the signaling contributes to various
chronic lung diseases including BPD and pulmonary fibrosis [39–
43]. Among Wnt signaling molecules, an essential component of
Wnt ligand-receptor complex, low-density lipoprotein receptor-
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e41596related protein 5 (LRP5), is known to be expressed in the lung [43]
andtoregulatepostnatalvasculardevelopmentintheretina[33,44–
46]andthelung [37,38,47].Forexample,Wnt7bcanbindtoFzd-1
and 210 receptors and cooperatively activate canonical Wnt
signaling in the presence of LRP5 and regulate lung airway and
vascular development[48].SincebothAng-Tie2andWntsignaling
pathways play an important role in vascular development in the
lung, we have explored the link between these two pathways to
elucidate the molecular mechanism underlying lung development.
In this report, we have demonstrated that LRP5 modulates
vascular development in the lung by stimulating Tie2 gene
expression in pulmonary microvascular endothelial cells and that
the balance between Ang1 and Ang2 determines the consequences
of LRP5/Tie2 signaling on angiogenesis and alveolar formation.
During physiological development when Ang1 is dominant in the
lung, loss of LRP5 causes impaired lung development. However,
in the mouse hyperoxia-induced BPD model when Ang2 is
dominant in the lung, downregulation of LRP5/Tie2 partially
protected neonatal lungs from developing the pathological pictures
of BPD. Although surfactant therapy, antenatal steroids, and
advances in the strategies of neonatal intensive care such as
ventilatory management have improved the survival of BPD
patients, BPD still remains a significant complication of premature
birth that is characterized by persistent respiratory problems
including a prolonged need for mechanical ventilation or oxygen
therapy, recurrent hospitalizations for frequent respiratory in-
fection and distress, and long-term exercise intolerance. Many
problems persist beyond childhood and cause a heavy socioeco-
Figure 1. Lrp5 controls Tie2 expression and lung vascular and alveolar formation in vivo.A ) H&E staining of the lungs from WT and
Lrp52/2 mice (P0 and P10) (left). Scale bar, 50 mm. Graph showing the mean linear intersect (MLI) in the lungs from WT and Lrp52/2 mice (P0 and
P10) (right, n=8, * p,0.01). B) mRNA levels of Tie2, VEGF, bFGF and PDGFa in the lungs from WT mice and Lrp52/2 mice at P0 and P10 (n=8,
*p,0.01). C) Immunofluorescence (IF) micrographs showing CD31-staining vessels (green), and Tie2 expression (magenta) in the lungs of WT (upper
panels) and Lrp52/2 mice (lower panels) at P10. Scale bar, 25 mm. Data are expressed as mean 6 s.e.m. throughout all figures.
doi:10.1371/journal.pone.0041596.g001
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understandings of the pathogenesis of BPD, which may improve
the current therapeutic strategies.
Results
LRP5 Controls Tie2 Expression in Lung Microvascular ECs
It has been reported that LRP5 plays important roles in lung
vascular and alveolar development [37,38,43,47] as well as retinal
angiogenesis [33,45,46,50]. Therefore, we first examined whether
Lrp5 regulates postnatal lung development using Lrp5 knockout
(Lrp52/2) mice. When we examined alveolar structure in the
lung using histological analysis, the subdivision of alveolar units
(septation) was incomplete and alveolar spaces were large at
postnatal day 0 (P0) in both wild type (WT) and Lrp52/2 mice
(Fig. 1A). Although extensive septation was developed in the lungs
at P10 in the WT mice (Fig. 1A), the septation was still incomplete
and alveolar spaces were large in Lrp52/2 mouse lungs at P10
(Fig. 1A). When alveolar structure was characterized using the
mean linear intercept (MLI) method, the MLI was significantly
lower in the lungs at P10 compared to that of P0 mouse lungs in
the WT mice, while there was not a significant difference between
P0 and P10 in the Lrp52/2 mice (Fig. 1A). Since the Ang-Tie2
pathway contributes to angiogenesis in the lung [23,24,30–32], we
examined Tie2 expression in the mouse lungs. Tie2 mRNA levels
were significantly lower in Lrp52/2 mouse lungs compared to
those in age-matched WT mouse lungs at P0 and P10 (Fig. 1B).
However, the expression of other factors known to be involved in
angiogenesis such as VEGF, bFGF and PDGFa was not
significantly different between WT and Lrp52/2 mouse lungs
at P0 and P10 (Fig. 1B). Immunofluorescent (IF) detection in tissue
sections shows that LRP5 and Tie2 proteins are specifically
expressed in ECs (CD31 positive cells) (Fig. S1, Fig. 1C) and
expression of Tie2 in the ECs is significantly decreased in the lungs
of Lrp52/2 mouse at P10 compared with that in the lungs of age-
matched WT mouse (Fig. 1C), suggesting that LRP5 regulates
septation during the postnatal period by changing the expression
of Tie2 in the capillary blood vessels.
Having established that LRP5 regulates Tie2 expression in
mouse lung ECs in vivo, we next examined whether LRP5 controls
Tie2 expression in human lung microvascular endothelial (L-
HMVE) cells in vitro. Knockdown of LRP5 using siRNA trans-
fection decreased both mRNA and protein levels of Tie2 in L-
HMVE cells by half, while LRP5 overexpression induced the
opposite effect (Fig. 2A, B). Importantly, LRP5 knockdown
decreased, while LRP5 overexpression increased b-catenin protein
levels in L-HMVE cells (Fig. 2B), suggesting that LRP5 controls
Tie2 expression in lung ECs via the canonical WNT signaling
pathway, in which b-catenin is degraded when it is inactive.
LRP5 and Tie2 Control Angiogenesis in Lung
Microvascular ECs
We then studied capillary tube formation of L-HMVE cells
cultured on Matrigel. Under low serum concentration (0.2%), the
ECs form incomplete tube structures on the gel (Fig. 3A, left
panel). The Tie2 agonist, Ang1 (50 ng/ml) enhanced the ability of
the cells to form tubes (Fig. 3A, second panel). Ang1-induced tube
formation was abrogated by decreased Tie2 expression levels in
the ECs through knockdown of Tie2 (Fig. 3A, third panel) or
LRP5 (Fig. 3A, right panel). Knockdown of Tie2 in ECs using
siRNA treatment had little effect on apoptosis when examined
using TUNEL assay (Fig. S2). LRP5 overexpression, which
upregulates Tie2, enhanced tube formation in the presence of
Ang1 and these effects were inhibited by Tie2 knockdown (Fig. 3B).
Importantly, LRP5 overexpression inhibited endothelial tube
formation when cultured with Ang2 (Fig. 3C). These results
suggest that LRP5 regulates angiogenesis by changing the
expression of Tie2 and that the balance of antagonistic Tie2
ligands, Ang1 and Ang2, determines the effects of LRP5 on
angiogenesis in vitro.
Lung Angiogenesis is Regulated by LRP5 and Tie2 in vivo
To further evaluate the role of LRP5 on angiogenesis and
alveolar formation in vivo, we implanted Matrigel on living young
adult mouse lungs for 10 days. Vascular network formation and
recruitment of both type I and II lung epithelium (as shown with
their respective markers aquaporin5 (AQ5) and surfactant protein-
A (SP-A)) along the vasculature were observed in the gels
implanted on WT mouse lungs (Fig. 4, upper panels). However,
these structures were not formed in the gels implanted on Lrp52/
2 mouse lungs (Fig. 4, 2nd panels) or in the gels with Tie2
inhibitor (10 mM) (Fig. 4, 3rd panels). These findings support the
hypothesis that LRP5/Tie2 signaling plays a crucial role in
angiogenesis and alveolar formation.
Hyperoxia Disrupts Lung Vascular Formation Through
the LRP5-Tie2 Pathway
Our in vitro results suggest that the LRP5/Tie2 signaling
pathway regulates lung vascular development through the balance
of Ang1 and Ang2 (Fig. 3). It has been reported that exposure of
neonatal mice to hyperoxia results in arrest of postnatal lung
development [31,42,51]. When we exposed neonatal mice to high
oxygen (75% O2) for 10 days (P1–P10), mRNA levels of Lrp5 and
Tie2 in the lungs increased by three- and two-fold, respectively,
Figure 2. LRP5 controls Tie2 expression in ECs. A) Graphs
showing Tie2 and LRP5 mRNA levels in L-HMVE cells treated with LRP5
siRNA (left) or retroviral vectors encoding LRP5 (right) (*p,0.01). B)
Immunoblots showing Tie2, LRP5, b-catenin and GAPDH protein levels
in L-HMVE cells treated with LRP5 siRNA (left) or retroviral vectors
encoding LRP5 (right). Error bars represent s.e.m. of at least three replica
experiments.
doi:10.1371/journal.pone.0041596.g002
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PLoS ONE | www.plosone.org 3 July 2012 | Volume 7 | Issue 7 | e41596Figure 3. LRP5 and Tie2 control angiogenesis in L-HMVE cells. A) Micrographs showing in vitro tube formation induced by Ang1 (50 ng/ml)
in L-HMVE cells (under 0.2% FBS). The cells were transfected with siRNA against Tie2 or LRP5. Scale bar, 50 mm. Graphs showing Tie2 mRNA levels in L-
HMVE cells (left), the mean tube length per field (middle) and the number of branch points (right) from ten fields (*p,0.01). B) Micrographs showing
in vitro tube formation induced by Ang1 (50 ng/ml) in L-HMVE cells (under 0.2% FBS) treated with retrovirus encoding LRP5 or in combination with
Tie2 siRNA. Scale bar, 50 mm. Graphs showing the mean tube length per field and the number of branch points from ten fields (*p,0.01). Error bars
represent s.e.m. of at least three replica experiments. C) Micrographs showing in vitro tube formation induced by Ang2 (50 ng/ml) in L-HMVE cells
treated with retrovirus encoding LRP5. Scale bar, 50 mm. Graphs showing the mean tube length and the number of branch points from ten fields
(*p,0.01). Error bars represent s.e.m. of at least three replica experiments.
doi:10.1371/journal.pone.0041596.g003
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control lungs (Fig. 5A). However, the lungs exposed to high oxygen
failed to make septation, resulting in fewer and larger alveoli with
less developed vascular structures that mimic the lungs of human
premature infants with BPD (Fig. 5B upper and second panels,
Fig. 5C). In situ hybridization (ISH) analysis confirmed that the
LRP5 and Tie2 mRNA levels were higher in the lungs exposed to
hyperoxia (Fig. 5B third and bottom panels). Importantly, mRNA
levels of Ang2 were four-times higher in the lungs exposed to
hyperoxia, while Ang1 levels remained the same compared with
control lungs (Fig. 5D), consistent with the report for human
premature infants with BPD [52]. These data are also consistent
with our in vitro data showing that Ang2 disrupts capillary
endothelial tube formation when LRP5/Tie2 signaling is activated
(Fig. 3C). Administration of Ang1 (500 ng, i.p., every other day),
an antagonist of Ang2 over the Tie2 receptor, restored impairment
of the alveolar development induced by exposure to high oxygen
(Figs. 6A, B) and these pathological phenotypes were also partially
rescued in Lrp52/2 mice (Figs. 6A, B) in which Tie2 expression
in the lung was low (Fig. 6C). Given that the exposure to hyperoxia
increases the level of Ang2 in Lrp52/2 mice (Fig. 6D), hyperoxia
may deregulate lung vascular and alveolar formation through the
enhancement of endothelial LRP5/Tie2/Ang2 signaling in the
postnatal lung.
Discussion
Here we show that angiogenesis and alveolar formation in the
lung can be suppressed by both activation and suppression of Wnt
signaling depending on the balance between Ang1 and Ang2. In
normal postnatal lung development where the ratio of Ang1and
Ang2 is in favor of Ang1, knockdown of LRP5, an essential
component of the canonical Wnt signaling pathway [53,54],
decreases the expression of Tie2 in ECs and hence inhibits
physiological neonatal lung vascular and alveolar formation. On
the contrary, during a pathological condition such as hyperoxia-
induced lung injury, in which Ang2 is dominant, activated LRP5/
Tie2 signaling inhibits angiogenesis and alveolar formation in the
neonatal lungs (Fig. 7). These findings suggest the opposite roles of
Figure 4. LRP5 regulates endothelial and epithelial cell recruitment in the gels implanted on mouse lungs. IF micrographs showing
in vivo angiogenesis and alveolar formation in the Matrigel implanted on the mouse lungs. The gels were implanted on the lungs of WT mice (upper
panels) or Lrp52/2 mice (middle panels). The gels with Tie2 inhibitor (bottom panels) were also implanted on the lung of WT mice. IF micrographs
detecting CD31-positive blood vessels (green), AQ5- positive type I epithelium (magenta, left panels) or SP-A-positive type II epithelium (magenta,
right panels). Scale bar, 50 mm. Graphs showing the projected areas of blood vessels and epithelium from ten fields (n=8, *p,0.01). Error bars
represent s.e.m.
doi:10.1371/journal.pone.0041596.g004
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PLoS ONE | www.plosone.org 5 July 2012 | Volume 7 | Issue 7 | e41596Figure 5. Hyperoxia regulates lung vascular formation via Lrp5 and Tie2 in vivo.A ) Graphs showing mRNA levels of Lrp5 and Tie2 in
neonatal mouse lungs treated with normoxia (21% O2) or hyperoxia (75% O2) for 10 days (n=8, *p,0.01). B) Light (H&E-stained) micrographs (top), IF
micrographs (2nd) showing formation of CD31-positive blood vessels (green, indicated by arrows) and AQ5-positive type I epithelium (magenta,
indicated by arrowheads), and ISH images (3
rd and bottom) detecting Lrp5 and Tie2 in neonatal mouse lung treated with normoxia (21% O2)o r
hyperoxia (75% O2) for 10 days. Scale bars, 50 mm for top, third and bottom panels, 25 mm for second panels. C) Graphs showing MLI (upper) and the
mean number of CD31-positive blood vessels segments per field (that is, segments between branch points) in alveolar septa (lower, n=8, *p,0.01).
D) Graphs showing Ang1 and Ang2 mRNA levels in neonatal mouse lungs treated with normoxia (21% O2) or hyperoxia (75% O2) for 10 days (n=8,
*p,0.01). Error bars represent s.e.m.
doi:10.1371/journal.pone.0041596.g005
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PLoS ONE | www.plosone.org 6 July 2012 | Volume 7 | Issue 7 | e41596LRP5-Tie2 signaling pathway in the regulation of lung vascular
and alveolar development in physiological and pathological
conditions, which depends on the balance between Ang1 and
Ang2.
In addition to transport of oxygen and nutrients to the organs,
angiogenic factors and ECs themselves represent a crucial source
of instructive signals to non-vascular tissues during lung de-
velopment [55–56] as well as adult lung alveolar regeneration
[57,58]. In fact, we have demonstrated that angiogenic factor
receptor Tie2 and its regulator LRP5 control vascular network
formation and alveolar morphogenesis in our Matrigel implanta-
tion model on the lung. Therefore, blood vessels in the lung seem
to actively guide normal alveolar development through the LRP5/
Tie2/Ang signaling system. However, since Tie2 knockout mice
die in utero while Lrp5 knockout mice survive, there may be other
compensatory pathways that modulate Tie2 expression in the
developing lung. Furthermore, Wnt ligands such as Wnt2, Wnt5a,
Wnt7b and Wnt11 are expressed in the epithelium and
mesenchyme of the lung [38] [56] and activation of the Wnt
pathway in these components also plays an important role in lung
development [59], suggesting that lung development may be
regulated by a complex series of reciprocal interactions of blood
vessels and these components.
Precise spatiotemporal regulation of antagonistic Ang1 and
Ang2 signaling [30] is required for postnatal lung capillary
network formation [60]; Ang2 is expressed by ECs located at the
leading edge of proliferating vessels and acts as a destabilizing
factor in areas of vascular remodeling [61,62], while Ang1 induces
translocation of Tie2 receptors to cell-cell contact or cell-matrix
interface to stabilize endothelial cell-cell junction integrity or to
regulate EC migration [22,63]. Importantly, in Tie2-deficient
mice, vascular plexus fails to remodel or mature and does not
develop beyond the primitive stage [64] and the endothelial cell
adherence and interaction with perivascular cells and ECM are
deregulated [65]. The Ang-Tie2 system in ECs also regulates
ECM remodeling which is necessary for organ formation [66].
Thus, the precise regulation of Tie2 signaling through a switch of
soluble ligands Ang1 and Ang2 expression plays an important role
in normal postnatal lung development [21,27] as well as in
pathological conditions such as BPD [11,28,29]. We have found
that hyperoxia increased the expression of LRP5, Tie2 and Ang2
and inhibited the lung development in neonatal mice, which was
attenuated in Lrp52/2 mice in which Tie2 expression was
downregulated. Thus, LRP5-Tie2 signaling has dual roles in
angiogenesis and alveolar development in a context-dependent
way [67,68]. However, Ang2 treatment alone did not disrupt lung
vascular and alveolar formation as we observed in hyperoxia
treated mice (data not shown). Other factors together with Ang2
may contribute to the pathogenesis of hyperoxia-induced lung
injury. Given that LRP5 is required for embryonic and postnatal
Figure 6. Ang1 rescues hyperoxia-induced lung injury in vivo.A )H&E-stained light micrographs showing the lungs of WT mice (P10) treated
with normoxia (21% O2), hyperoxia (75% O2) with or without Ang1, or the lungs of Lrp52/2 mice (P10) treated with hyperoxia for 10 days. Scale bar,
25 mm. B) Graphs showing MLI of the lungs in each condition described in A) (n=8, *p,0.01). C) Graphs showing the Tie2 mRNA levels in neonatal
WT or Lrp52/2 mouse lungs treated with normoxia (21% O2) or hyperoxia (75% O2) for 10 days (n=8, *p,0.01). D) Graphs showing Ang1 and Ang2
mRNA levels in neonatal Lrp52/2 mouse lungs treated with normoxia (21% O2) or hyperoxia (75% O2) for 10 days (n=8, *p,0.01). Error bars
represent s.e.m.
doi:10.1371/journal.pone.0041596.g006
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formation [33,44–46,69], the LRP5/Tie2/Angs signaling systems
may also contribute to the development of these organs.
In summary, here we first demonstrate that the LRP5-Tie2
pathway controls neonatal vascular and alveolar development in
an Angs-dependent way. This pathway also contributes to the
pathogenesis of hyperoxia-induced lung injury in the neonate.
Thus, modulation of the LRP5-Ang/Tie2 system is likely to lead
to the identification of new therapeutic targets for neonatal
pulmonary diseases such as BPD.
Materials and Methods
Materials
Anti-Tie2 monoclonal, anti-LRP5, -b-catenin, -AQ5, b-GAL
polyclonal antibodies were from Abcam. Anti -CD31 monoclonal
antibodies were from BD Biosciences (San Diego, CA). Anti–
GAPDH monoclonal antibody was from Chemicon. Anti-SP-A
polyclonal antibody was from Millipore. Ang21 and 22 were
from R & D systems (Minneapolis, MN). Tie2 inhibitor was from
BioMol/Enzo Life Science. L-HMVE cells (Cambrex, Walkers-
ville, MD) were cultured in EBM2 medium containing 5% FBS
and growth factors (VEGF, bFGF and PDGF) for all experiments
except the in vitro tube form assays with Ang1 and Ang2 in which
we used EBM2 with 0.2% serum.
Animals Experiments
All animal studies were reviewed and approved by the Animal
Care and Use Committee of Boston Children’s Hospital. Unless
otherwise indicated, C57BL/6 mice (stock no. 664; Jackson
Laboratory) were used for the study. The Lrp52/2 mice (stock
no. 005823; Jackson Laboratory) were developed by Deltagen Inc
[70]. For hyperoxia-induced lung injury, newborn pups were
subdivided into two groups and exposed to 75% O2 in a Plexiglas
chamber or 21% O2 within 24 hours of birth [51]. Dams were
rotated from hyperoxia to room air every 24–48 hours to prevent
excessive oxygen toxicity to the adult animals. At P10, lungs were
harvested for histological and mRNA analysis.
Lung Morphometry
Lungs were fixed with 4% paraformaldehyde solution through
the trachea under a constant pressure of 20 cm H2O. The trachea
was then ligated, and the lungs were immersed in fixiative
overnight at 4C. Lungs were processed and embedded in OCT
compound [70]. Serial step sections, 5 mm in thickness were taken
along the longitudinal axis of the lobe. The fixed distance between
the sections was calculated so as to allow systematic sampling of 10
sections across the whole lobe. Lungs were analyzed by
hematoxylin and eosin (H&E) staining, IHC and ISH [71,72].
The Lrp5 gene was targeted mutated and a bacterial lacZ gene
was inserted into the gene such that the endogenous Lrp5 gene
promoter drives expression of beta-galactosidase. To visualize lacZ
gene, immunostaining was performed with anti-b-GAL antibody
on lung tissue sections. Probes for ISH were produced using
primers: Lrp5 sense (59-GCGGAGTGAAGCTGGAGTCC-39)
and antisense (59-GTAATACGACTCACTATAGGGCCTCG-
CATGGTGTGTGGAAGGG-39), Tie2 sense (59-AG-
GAGTCTGGGTCTGCAG-39) and antisense (59-GGGATCCG-
GATTGTTTTTGG-39) as described previously [72]. Alveolar
structures were quantified on a motorized microscope stage using
mean linear intercept (MLI) method [73].
Plasmid Construction, Gene Knockdown, Biochemical
and Molecular Biological Methods
For virus construction, the full-length myc-Lrp5 (mouse) was
constructed by PCR using full length plasmids from Open
Biosystems as a template and subcloned into the pOC retroviral
backbone vector at the NotI/BamHI sites. The generation of viral
Figure 7. LRP5 regulates lung vascular and alveolar development through the Ang-Tie2 pathway. Angiogenesis and alveolar formation
in the lung can be controlled by LRP5-Tie2 signaling depending on the Ang1/Ang2 ratio. In normal postnatal lung development where Ang1 is
dominant, LRP5, an essential component of the canonical Wnt signaling pathway, increases Tie2 expression in ECs and stimulates (downward arrow
symbols) neonatal lung vascular and alveolar development. However, LRP5-Tie2 signaling inhibits (T-bar symbol) vascular and alveolar development
when the lungs are exposed to hyperoxia in which Ang2 is upregulated.
doi:10.1371/journal.pone.0041596.g007
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performed using the RNA interference technique [71]. siRNA for
human LRP5 (59-GCCCUACAUCAUUCGAGGAAU-39 and
59-AUUCCUCGAAUGAUGUAGGGC-39) was purchased from
Sigma Genosys (St. Louis, MO). siRNA for human Tie2 was
a smart pool siRNA from Dharmacon. As a control, siRNA duplex
with irrelevant sequence (QIAGEN) was used. Quantitative
reverse transcription (qRT)-PCR was performed with the
Quantitect SYBR Green RT-PCR kit (QIAGEN) using ABI
7300 real time PCR system (Applied Biosystems, Foster City, CA).
b2 microglobulin or cyclophilin controlled for overall cDNA
content. The primers used are shown in Table S1.
Cell Analysis Methods
For the in vitro angiogenesis assay, L-HMVE cells (10
4 cells per
150 ml of EBM-2 with 0.2% serum) were plated on Matrigel (BD
Biosciences), and incubated for 12–16 h in the presence of Ang1
or Ang2 (50 ng/ml); tube formation was assessed using total tubule
length as well as the number of tubule branch points in ten
random fields [71]. The cell apoptosis was assessed using TUNEL
assay (Roche).
In vivo Matrigel Implantation Assay
The cross-linked Matrigel with specific elasticity was cast in
PDMS molds as described previously [71] and the molds were
implanted on the lungs of living mice. The mice were anesthetized
with tribromoethanol (Avertin) and intubated with a plastic 21-
gauge cannula for mechanical ventilation (Harvard Apparatus).
An incision was performed in the fifth, left intercostal space and
extended to the pleural cavity. After peeling the areas of visceral
pleura with the fine forceps (0.560.5 mm square area), the plugs
were glued over the area using PeriAcrylH90 (Glustitch). After
confirming homeostasis, the thorax and skin were closed with silk
suture and the mechanical ventilation was terminated to recover
the mice. After 10 days, the mice were euthanized and the molds
containing the gel were harvested for histological analysis.
Immunostaining was performed on the cryosectioned samples as
described [71]. Stacks of optical sections (20 mm thick) were
compiled to form three-dimensional images using Volocity 4.4
(Improvision, PerkinElmer).
Statistical Analysis
Error bars (SEM) and p values were determined from the results
of three or more repeated experiments. The unpaired T test after
ANOVA was used for analysis of statistical significance.
Supporting Information
Figure S1 LRP5 localizes in endothelial cells in the
neonatal lung. IF micrographs showing CD31-positive blood
vessels (green) and LRP5 expression (magenta) in the lungs of WT
mice at P10. Scale bar, 20 mm.
(TIF)
Figure S2 Tie2 siRNA has no effects on apoptosis in L-
HMVE cells. IF micrographs showing TUNEL staining of
control and Tie2 siRNA-treated L-HMVE cells. Scale bar, 50 mm.
(TIF)
Table S1 The sequences for primers for qRT-PCR.
(DOC)
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